• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Abbott’s next-gen FreeStyle Libre wins CE Mark

October 1, 2018 By Sarah Faulkner

Abbott logo updatedAbbott (NYSE:ABT) said today that its next-generation FreeStyle Libre system won CE Mark clearance in the European Union.

The glucose monitor, which eliminates the need for finger sticks, features optional alarms that users can customize, according to Abbott.

“The FreeStyle Libre 2 system is designed to further empower people with diabetes by providing a choice about how they want to use alarms—which can be a valuable feature for a specific group of people managing their diabetes,” Jared Watkin, SVP of Abbott’s diabetes unit, said in prepared remarks. “We′re committed to developing the latest health technology to help people lead fuller lives. Our goal is to make FreeStyle Libre widely accessible, which includes offering additional features at no additional cost to our customers.”

The FreeStyle Libre 2 system includes alarms to alert the user when it detects low and high glucose and an alarm to notify the user when the sensor can’t communicate with the reader. Users can decide if they want to receive alarms and if they want to be alerted via sound or vibration. Consistent with Abbott’s first-gen FreeStyle Libre monitor, users can also track glucose trends and patterns and view an eight-hour glucose history.

“Enabling patients to have optional alarms with the FreeStyle Libre 2 system provides them with even more freedom in managing their condition,” Dr. Jens Kröger, specialist at the Center of Diabetology Bergedorf, added. “For some patients who are unaware of the hypoglycemia episodes they may be experiencing – especially during sleep – having alarms can be important. Or, for the parents of children with diabetes, alarms can provide peace of mind.”

Abbott noted that the FreeStyle Libre 2 device will be available on a rolling basis throughout Europe in the coming weeks. The updated system’s price will be the same as the first-gen FreeStyle Libre, the medtech company reported.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Diabetes, Featured, Regulatory/Compliance, Wall Street Beat Tagged With: abbott

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS